Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2015 | original article | Ausgabe 11-12/2015

Wiener klinische Wochenschrift 11-12/2015

Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream

Wiener klinische Wochenschrift > Ausgabe 11-12/2015
MD, PhD Helga Sertić Milić, PhD Ana Franjević, PhD Gordana Bubanović, MD, PhD Ante Marušić, MD, PhD Igor Nikolić, MD, PhD Igor Puljić



The computed tomography (CT) is the “golden standard” for the assessment of lung cancer progression due to its ability to clearly display the radiomorphologic characteristics. As lung cancer mortality is very high, more comprehensive approaches may be needed for its earlier diagnosis. The research hypothesis was to investigate the relation between the CT morphologic characteristics (size, stage, and edges) of pulmonary lesion and the extent of release of a soluble fragment of cytokeratin 19 being a part of the cytoskeleton of lung epithelial cells.


This is a retrospective study including 246 pulmonary lesions being diagnosed and subsequently treated at the University Hospital Centre Zagreb, Croatia. The information about the relevant clinical, radiological, and laboratory facts was collected at the time of diagnosis in 164 NSCLC patients, 52 patients with pulmonary metastases, and 30 benign cysts. CYFRA 21-1 was determined by electrochemiluminescence immunoassay. The nonparametric statistical methods were applied.


There was a positive correlation between the size and CYFRA 21-1 in NSCLC unlike metastases or cysts (p = 0.0001). The highest values of CYFRA 21-1 were seen in advanced stages of NSCLC and lesions with spiculated edges.


The level of CYFRA 21-1 positively correlates with the greatest size of NSCLC measured by CT. The differences in CYFRA 21-1 according to TNM classification are significant (p = 0.0001): higher values were observed in advanced stages and with tumors having spiculated, lobulated, and poorly defined edges. The combination of CYFRA 21-1 and CT may help articulate the malignancy of pulmonary lesions.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 11-12/2015

Wiener klinische Wochenschrift 11-12/2015 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

mitteilungen der gesellschaft der ärzte in wien